Here, we present a refined protocol to effectively reveal biotinylated dextran amine (BDA) labeling with a fluorescent staining method through a reciprocal neural pathway. It is suitable for analyzing the fine structure of BDA labeling and distinguishing it from other neural elements under a confocal laser scanning microscope.
High molecular weight biotinylated dextran amine (BDA) has been used as a highly sensitive neuroanatomical tracer for many decades. Since the quality of its labeling was affected by various factors, here, we provide a refined protocol for the application of high molecular weight BDA for studying optimal neural labeling in the central nervous system. After stereotactic injection of BDA into the ventral posteromedial nucleus (VPM) of the thalamus in the rat through a delicate glass pipette, BDA was stained with fluorescent streptavidin-Alexa (AF) 594 and counterstained with fluorescent Nissl stain AF500/525. On the background of green Nissl staining, the red BDA labeling, including neuronal cell bodies and axonal terminals, was more distinctly demonstrated in the somatosensory cortex. Furthermore, double fluorescent staining for BDA and the calcium-binding protein parvalbumin (PV) was carried out to observe the correlation of BDA labeling and PV-positive interneurons in the cortical target, providing the opportunity to study the local neural circuits and their chemical characteristics. Thus, this refined method is not only suitable for visualizing high quality neural labeling with the high molecular weight BDA through reciprocal neural pathways between the thalamus and cerebral cortex, but also will permit the simultaneous demonstration of other neural markers with fluorescent histochemistry or immunochemistry.
High molecular weight BDA (10,000 molecular weight), a highly sensitive tracer, has been used for tracing neural pathways in the central nervous system for over 20 years1. Although the use of the BDA is a common neural tract tracing technique, the quality of BDA labeling can be affected in animals by various factors1,2,3. Our recent study indicated that the optimal structure of BDA labeling is not only associated with a proper post-injection survival time, but also correlated with the staining method4. Until now, conventional avidin-biotin-peroxidase complex (ABC), streptavidin-fluorescein isothiocyanate, and streptavidin-AF594 staining methods were used for revealing the BDA labeling in previous studies2,3,4,5. In comparison, fluorescent staining for BDA can be easily performed.
In order to extend the application of high molecular weight BDA, a refined protocol was introduced in the present study. Following the injection of BDA into the VPM of the thalamus in the rat brain, BDA labeling was revealed by the regular method of standard ABC staining as well as by double fluorescent staining, which was carried out for observing the correlation of BDA labeling and basic neural elements or interneurons in the cortical target with streptavidin-AF594 and fluorescent Nissl histochemistry or PV-immunochemistry, respectively. Through the reciprocal neural pathways between VPM and the primary somatosensory cortex (S1)6,7,8, we focused our observation on BDA labeling in the thalamocortical projected axons and corticothalamic projected cell somas in the S1. By this process, we expected to provide not only a detailed protocol for obtaining the high quality of neural labeling with high molecular weight BDA, but also a refined protocol on the combination of fluorescent BDA labeling and other fluorescent neural markers with histochemistry or immunochemistry. This approach is preferable to study the local neural circuits and their chemical characteristics under a confocal laser scanning microscopy.
This study was approved by the ethics committee at the China Academy of Chinese Medical Sciences (reference number 20160014). All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, D.C., 1996). Four adult male rats (weight 250-280 g) were used in this study. All animals were housed in a 12 h light/dark cycle with controlled temperature and humidity, and allowed free access to food and water. The instruments and materials used in the present study were showed in Figure 1. Before the surgery, all instruments, such as stereotaxic frame and glass pipette, were cleaned using 70% ethanol.
1. Surgical Procedures
2. Perfusions and Sections
3. Standard ABC Staining
NOTE: Free floating sections from every third coronal section of the brain were used for visualizing the BDA labeling with standard ABC procedure10.
4. Double Fluorescent Staining for BDA and Basic Neural Elements in Cerebral Cortex
NOTE: In contrast, double fluorescent staining was carried out for observing the correlation of BDA labeling and basic neural elements on the adjacent sections to the above used with streptavidin-AF594 and counterstained with fluorescent Nissl stain AF500/525.
5. Double Fluorescent Staining for BDA and Interneurons in Cerebral Cortex
NOTE: Double fluorescent staining was carried out for observing the correlation of BDA labeling and interneurons on the representative sections in the cortical target with streptavidin-AF594 and PV-immunochemistry.
6. Observation
Survival of 10 days post injection of BDA into the VPM was sufficient for producing intense neural labeling on the corresponding cortical areas ipsilateral to the injection side (Figure 2). Both conventional ABC and fluorescent staining procedures for BDA revealed the similar pattern of neural labeling on the S1, including anterogradely labeled thalamocortical axons and retrogradely labeled corticothalamic neurons (Figure 2C, D).
For the anterogradely labeled axons, they were observed from layer 2 to layer 6 with higher density on the layer 4, and the typical type of thalamocortical axons was observed in the barrel area (Figure 2C, D). In the higher magnification view, BDA labeling clearly presented on the axonal trunk, branches, collaterals, and small varicosities (Figure 3A). Under the labeled thalamocortical axons to be displayed, the retrogradely labeled cortical pyramidal neurons were displayed, and their cell bodies distributed on the layers 5/6, but their apical dendrites extended to layer 2 (Figure 2C, D). The BDA labeling not only presented in the neuronal cell bodies and dendrites, but also in dendritic spines, appearing as Golgi-like resolution (Figure 3B).
In addition, double fluorescent staining was also performed for observing the correlation of BDA labeling and interneurons in the cortical target with streptavidin-AF594 and PV-immunochemistry. Around the BDA labeling in the cortical target, PV-positive neurons were distributed from layer 2 to layer 6 with high concentration in layer 4 (Figure 4A). There were no PV-positive neurons to be labeled with BDA, however, BDA-labeled axonal terminals were found around the surface of PV-positive cell bodies and PV-positive axonal terminals around BDA-labeled cortical pyramidal neurons (Figure 4B, C).
Figure 1. Photographs of key surgical steps and main instruments to be used in this experiment.
A: The stereotaxic device. B: The dental drill. C: Surgical tools (scalpel, microforceps, and etc.) D: Micro-syringe equipped with a glass micropipette. E: Place the rat head into the stereotaxic device. F: Clean the surgical site. G: Confirm the Bregma point. H: Drill the skull. I: Expose the cerebral cortex. J: Load 10% BDA into the micro-syringe. K: Mount the syringe into the apparatus for micro-injection. L: Adjust the speed of the micro-pump. M: Insert the glass micropipette into the VPM. N: Suture the wound with sterile thread. O: Perfuse the rat in the hood. P: Dissect out the brain. Q: Divide the brain into three blocks with the brain matrices. R: Cut the brain on a freezing stage sliding microtome system. S: Collect brain sections orderly in a 6-well dish. T: Mount the sections on microscope slides. Please click here to view a larger version of this figure.
Figure 2. Injection site and typical neural labeling with high molecular weight BDA in the somatosensory cortex.
A: Injection site was determined on a stereotaxic atlas. B: Representative photomicrograph showing the injection site of BDA (red) in the ventral posteromedial nucleus of thalamus (VPM) on the background of green Nissl staining. C: Photomicrograph of fluorescent BDA labeling, including thalamocortical axons in layer 4 and corticothalamic neurons in layers 5/6. D: Photomicrograph of conventional BDA labeling with a standard avidin-biotin-peroxidase procedure showing the similar pattern of neural labeling to fluorescent BDA labeling. VPL, ventral posterolateral nucleus of the thalamus. Please click here to view a larger version of this figure.
Figure 3. High quality of neural labeling with high molecular weight BDA on the background of green Nissl staining.
A: Higher magnification view of the anterogradely labeled axonal arbors (red) in detail. B: High resolution photographs showing the retrogradely labeled neuronal cell body, dendrites, and dendritic spines (red) in detail. Please click here to view a larger version of this figure.
Figure 4. The correlation of BDA labeling and calcium-binding protein PV-positive interneurons in the cortical target.
A: The distribution of BDA labeling (red) and PV-positive interneurons (green) in the somatosensory cortex. B: Higher magnification view of the distribution of BDA-labeled axons and PV-positive interneurons in layer 4. C: High resolution photograph of BDA-labeled cortical pyramidal cell (red) and PV-positive interneurons (green) in layers 5/6. All samples were counterstained with DAPI (blue). Please click here to view a larger version of this figure.
Supplemental Video Files: The supplemental videos briefly show the surgical procedure, injection of BDA into the VPM, perfusion and sectioning, and results. In the video file named "IV. Representative Result", the three-dimensional confocal laser scanning microscopy and analysis system results are shown. High resolution animation shows the retrogradely labeled neuronal cell body, dendrites, and dendritic spines (red) in detail. Please click here to download this file.
Selecting a proper tracer is a critical step for a successful neural tracing experiment. In the family of BDA, high molecular weight BDA (10,000 molecular weight) was recommended to be preferentially transported through the anterograde neural pathway in contrast to low molecular weight BDA (3,000 molecular weight)2,3,11,12,13. However, many studies also suggested that high molecular weight BDA might also be potentially used for retrograde pathway tracing in parallel with anterograde tracing1,2,3. Through the reciprocal neural pathways between VPM and S1, we provided further evidence to support the idea that high molecular weight BDA is suitable for bidirectional tract tracing4. In a similar way in this domain, high molecular weight BDA was also used in the visual and auditory system for examining the reciprocal connections between the dorsal lateral geniculate body and visual cortex as well as the medial geniculate body and auditory cortex3,14.
In the neural tracing experiment, the other important consideration is the choice of staining method for the neural labeling. In most of the previous studies, both the conventional ABC protocol and fluorescent streptavidin staining method have been used for examining BDA labeling and revealed the similar morphological pattern1,2,3,4,5. Here, we found that streptavidin-AF594 was not only a proper choice for BDA labeling, but also suitable for combining with other neural marker, such as fluorescent Nissl and PV-antigen, providing a new opportunity for observing the correlation of BDA labeling and other neural elements. Although the conventional double-staining method for BDA and other neural markers were also frequently carried out with the two-color DAB procedure14,15, it is not suitable for using a three-dimensional analysis system under a confocal laser scanning microscopy. From a technical standpoint, our present study provides a valuable reference to distinctly compare between BDA labeling and other labeling.
The neural tract tracing technique was initially used for revealing neuronal connections between the injection site and its target in the nervous system; however, researchers still were in pursuit of the ideal structure of neural labeling with a proper tracer16,17. In contrast to other tracers, such as horseradish peroxidase and subunit B of cholera toxin, high molecular weight BDA produces the higher quality of neural labeling for quantifying the number of axonal arbors and neuronal dendrites16,17. Although the quantitative analysis of BDA labeling was not carried out in the present study, the higher quality of neural labeling with BDA provides more opportunities to closely understand the morphological characteristics on labeled axonal arbors and neuronal dendrites.
Similar to the application of many other tracers, a series of important issues should be considered for this experimental procedure, including: the concentration and volume of BDA used for injection, correct site of injection, the tip diameter of the glass pipette, surgical process, optimal survival time, perfusion, section, and observation under a microscope. It is directly associated with the quality of BDA labeling what we expected. In addition to the critical steps mentioned above, there are technical limitations that require attention, such as the distance from the injected site to the labeled target, which is dependent on the model animal species used in the experiment3,5,18. In a word, a successful tracing study depends on every step in the entire experimental procedure.
In the present study, we have provided a refined protocol to demonstrate that the fluorescent BDA staining method is an effective way for obtaining the high quality of neural labeling, which can be simultaneously combined with other neural markers by using fluorescent histochemistry or immunochemistry. Comparing the conventional BDA staining with the DAB procedure, we can more easily analyze the fine structure of BDA labeling and distinguish it from other neural elements in the tracing target under a confocal laser scanning microscopy by the present fluorescent approach.
The authors have nothing to disclose.
This study was funded by the National Natural Science Foundation of China (Project Code no. 81373557; no. 81403327).
Biotinylated dextran amine (BDA) | Molecular Probes | D1956 | 10,000 molecular weight |
Streptavidin-Alexa Fluor 594 | Molecular Probes | S32356 | Protect from light |
500/525 green fluorescent Nissl stain | Molecular Probes | N21480 | Protect from light |
Brain stereotaxis instrument | Narishige | SR-50 | |
Freezing microtome | Thermo | Microm International GmbH | |
Confocal imaging | Olympus | FV1200 | |
system | |||
Micro Drill | Saeyang Microtech | Marathon-N7 | |
Sprague Dawley | Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences | SCKX (JUN) 2012-004 | |
Vectastain ABC Kit | Vector Laboratories | PK-4000 | |
superfrost plus microscope slides | Thermo | #4951PLUS-001 | 25x75x1mm |
Photoshop and Illustration | Adobe | CS5 |